Results 41 to 50 of about 15,553 (191)

In-Vitro Selection of Ceftazidime/Avibactam Resistance in OXA-48-Like-Expressing Klebsiella pneumoniae: In-Vitro and In-Vivo Fitness, Genetic Basis and Activities of β-Lactam Plus Novel β-Lactamase Inhibitor or β-Lactam Enhancer Combinations

Antibiotics, 2021
Ceftazidime/avibactam uniquely demonstrates activity against both KPC and OXA-48-like carbapenemase-expressing Enterobacterales. Clinical resistance to ceftazidime/avibactam in KPC-producers was foreseen in in-vitro resistance studies.
Snehal Palwe, Yamuna Devi Bakthavatchalam, Kshama Khobragadea, Arun S. Kharat, Kamini Walia, Balaji Veeraraghavan   +5 more
doaj   +1 more source

Structural and Functional Aspects of Class A Carbapenemases. [PDF]

, 2016
The fight against infectious diseases is probably one of the greatest public health challenges faced by our society, especially with the emergence of carbapenem-resistant gram-negatives that are in some cases pan-drug resistant.
Dortet, L, Iorga, BI, Naas, T
core   +3 more sources

Synergy between Mecillinam and Ceftazidime/Avibactam or Avibactam against Multi-Drug-Resistant Carbapenemase-Producing Escherichia coli and Klebsiella pneumoniae

Antibiotics, 2022
Background: Carbapenemase-producing Klebsiella pneumoniae and Escherichia coli have become a significant global health challenge. This has created an urgent need for new treatment modalities.
Karoline Knudsen List, Mette Kolpen, Kasper Nørskov Kragh, Godefroid Charbon, Stine Radmer, Frank Hansen, Anders Løbner-Olesen, Niels Frimodt-Møller, Frederik Boetius Hertz   +8 more
doaj   +1 more source

New Antibiotics for the Treatment of Nosocomial Central Nervous System Infections

Antibiotics
Nosocomial central nervous system (CNS) infections with carbapenem- and colistin-resistant Gram-negative and vancomycin-resistant Gram-positive bacteria are an increasing therapeutic challenge. Here, we review pharmacokinetic and pharmacodynamic data and
Roland Nau, Jana Seele, Helmut Eiffert
doaj   +1 more source

The Klebsiella pneumoniae carbapenemase (KPC) β-Lactamase Has Evolved in Response to Ceftazidime Avibactam

Antibiotics, 2023
Klebsiella pneumoniae carbapenemase KPC is an important resistance gene that has disseminated globally in response to carbapenem use. It is now being implicated as a resistance determinant in Ceftazidime Avibactam (CAZ-AVI) resistance. Given that CAZ-AVI
Sona Garsevanyan, Miriam Barlow
doaj   +1 more source

Selection of mutants with resistance or diminished susceptibility to ceftazidime/avibactam from ESBL- and AmpC- producing Enterobacteriaceae [PDF]

, 2018
Introduction: Difficult Gram-negative infections are increasingly treated with new β-lactamase inhibitor combinations, e.g. ceftazidime/avibactam.
Doumith, Michel, Jamrozy, Dorota, Livermore, David M., Mushtaq, Shazad, Nichols, Wright W., Woodford, Neil   +5 more
core   +1 more source

All Roads Lead to Rome: Enhancing the Probability of Target Attainment with Different Pharmacokinetic/Pharmacodynamic Modelling Approaches

Antibiotics, 2023
In light of rising antimicrobial resistance and a decreasing number of antibiotics with novel modes of action, it is of utmost importance to accelerate development of novel treatment options.
Kashaf Khalid, Katharina Rox
doaj   +1 more source

Potent monoclonal antibodies against multidrug‐resistant hypervirulent Klebsiella pneumoniae

Interdisciplinary Medicine, EarlyView.
A novel immunization strategy using a low‐virulence, multidrug‐resistant strain yields synergistic monoclonal antibodies against hypervirulent Klebsiella pneumoniae. These antibodies provide cross‐serotype protection through a dual‐mechanism of pathogen clearance and immunomodulation, offering a promising non‐antibiotic therapeutic for resistant ...
Yushan Jiang, Zhuolin Li, Yang Yang, Zihan He, Tyuji Hoshino, Vladislav Victorovich Khrustalev, Qing Zhu, Weiling Wu, Wei Zhao, Chenguang Shen, Shi Ouyang   +10 more
wiley   +1 more source

Lung penetration, bronchopulmonary pharmacokinetic/pharmacodynamic profile and safety of 3 g of ceftolozane/tazobactam administered to ventilated, critically ill patients with pneumonia [PDF]

, 2020
Objectives: Ceftolozane/tazobactam is approved for hospital-acquired/ventilator-associated bacterial pneumonia at double the dose (i.e. 2 g/1 g) recommended for other indications.
Adedoyin, Adedayo, Caro, Luzelena, De Waele, Jan, Gadzicki, Elaine, Kuti, Joseph L, Larson, Kajal B, Nicolau, David P, Rhee, Elizabeth G, Yu, Brian, Zeng, Zhen   +9 more
core   +1 more source

Aztreonam-avibactam synergy, a validation and comparison of diagnostic tools

Frontiers in Microbiology, 2023
IntroductionAntimicrobial resistance is a growing problem that necessitates the development of new therapeutic options. Cefiderocol and aztreonam (AT) are often the last active β-lactams for treating metallo-β-lactamases (MBL)-producing Gram-negative ...
Gil Verschelden, Gil Verschelden, Maxim Noeparast, Anke Stoefs, Eveline Van Honacker, Kristof Vandoorslaer, Laura Vandervore, Margo Olbrecht, Kathleen Van Damme, Thomas Demuyser, Thomas Demuyser, Denis Piérard, Ingrid Wybo   +12 more
doaj   +1 more source